Karyopharm faces default risk with only a month left to rescue cancer expansion

Karyopharm Therapeutics, a commercial-stage cancer drugmaker, is confronting severe financial strain as its market capitalization is roughly one‑third of the revenue it expects to generate in 2026.

The company warned that it has only about a month remaining to secure the financing needed to keep its planned cancer expansion on track, putting it on the brink of default.

Without new capital, the firm’s growth initiatives could stall, raising concerns for investors and highlighting the challenges of funding ambitious oncology programs.